Programmed Cell Death News and Research

RSS

New research provides hope for treating stroke using HUCBCs

Researchers have known that transplanted human umbilical cord cells (HUCBCs) can have a restorative effect on the brain and brain function following a stroke. However, just how the cells exert their therapeutic effects has not been clear. Now, a research team from the University of South Florida using animal models of stroke has found that the HUCBCs are most beneficial in preventing neuron loss when the Akt signaling pathway is activated by secretions from the HUCBCs and that Akt activation subsequently impacts a specific gene involved in reducing inflammation.

10 Feb 2015

Study: Green tea compound may activate a cycle that kills oral cancer cells

A compound found in green tea may trigger a cycle that kills oral cancer cells while leaving healthy cells alone, according to Penn State food scientists. The research could lead to treatments for oral cancer, as well as other types of cancer.

28 Jan 2015

TSRI scientists find drug candidates that can prevent degeneration of brain cells in Parkinson's

In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have shown their drug candidates can target biological pathways involved in the destruction of brain cells in Parkinson's disease.

28 Jan 2015

Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

A study led by St. Jude Children's Research Hospital scientists has identified the population of white blood cells that tumors use to enhance growth and suppress the disease-fighting immune system.

19 Dec 2014

TUM researchers discover new mechanism for regulating programmed cell death

Programmed cell death is a mechanism that causes defective and potentially harmful cells to destroy themselves. It serves a number of purposes in the body, including the prevention of malignant tumor growth. Now, researchers at Technische Universität München have discovered a previously unknown mechanism for regulating programmed cell death.

18 Dec 2014

Eminent molecular cell biologist awarded GRC fellowship

The Gutenberg Research College of Johannes Gutenberg University Mainz has awarded the coveted GRC fellowship to Professor Krishnaraj Rajalingam. In the upcoming years, he will lead a research team at the Research Center for Immunotherapy at Mainz University.

26 Nov 2014

Research shows that immune checkpoint inhibitors may work in glioblastoma, brain metastases

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

23 Nov 2014

Chemotherapy drug combined with cancer-killing virus may treat recurrent ovarian cancer

In six out of 10 cases, ovarian cancer is diagnosed when the disease is advanced and five-year survival is only 27 percent.

14 Nov 2014

Unique immunochemotherapy approach to treating pancreatic cancer

VCU Massey Cancer Center and VCU Institute of Molecular Medicine researchers discovered a unique approach to treating pancreatic cancer that may be potentially safe and effective. The treatment method involves immunochemotherapy - a combination of chemotherapy and immunotherapy, which uses the patient's own immune system to help fight against disease.

13 Nov 2014

Melbourne researchers reveal key steps involved in programmed cell death

Melbourne researchers have uncovered key steps involved in programmed cell death, offering new targets for the treatment of diseases including lupus, cancers and neurodegenerative diseases.

31 Oct 2014

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

30 Sep 2014

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).

30 Sep 2014

Researchers reveal why RB1 gene mutations primarily cause retinoblastomas in children

Retinoblastoma is a childhood retinal tumor usually affecting children one to two years of age. Although rare, it is the most common malignant tumor of the eye in children.

25 Sep 2014

Promising new approach for combating colorectal cancer

Scientists at the University of York are working on a promising new approach for tackling colorectal cancer, the second most common cause of cancer-related death.

23 Sep 2014

Researchers pave way for development of new generation of chemotherapy drugs

A new mechanism to inhibit proteasomes, protein complexes that are a target for cancer therapy, is the topic of an article published in the journal Chemistry & Biology.

10 Sep 2014

Researchers examine impact of BIM deletion on survival outcomes of advanced NSCLC patients

Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients.

25 Aug 2014

Research validates Myc inhibition as effective therapeutic strategy for glioma

Research led by the Vall d'Hebron Institute of Oncology (VHIO) evidence the most conclusive preclinical results to-date validating Myc inhibition as a therapeutic strategy in glioma - a highly agressive tumor type that notoriously outsmarts current anti-cancer therapies.

19 Aug 2014

Researchers create synthetic ion transporter that triggers apoptosis in cancer cells

Researchers from the University of Southampton are part of an international team that has helped to create a molecule that can cause cancer cells to self-destruct by carrying sodium and chloride ions into the cells.

12 Aug 2014

Researchers create synthetic molecule that can cause cancer cells to self-destruct

Researchers from The University of Texas at Austin and five other institutions have created a molecule that can cause cancer cells to self-destruct by ferrying sodium and chloride ions into the cancer cells.